Primary hematological malignancy of the uterine cervix: A case report

Abstract

The present case report investigated the clinical characteristics of primary hematological malignancy of the uterine cervixin five patients. Among the five patients, three patients were diagnosed with non-Hodgkin's lymphoma (NHL) and two patients with myeloid sarcoma (MS) of the uterine cervix. Biopsies of the uterine cervices demonstrated the involvement of lymphoid cells or myeloid blasts cells. Immunohistochemical staining demonstrated the expression of B-lymphoid and myeloid lineage markers. The associated lysozyme, myeloperoxidase and mast/stem cell growth factor receptor (CD117) markers were specific for the diagnosis of MS. The three patients with NHL survived, and one of the patients survived for 82 months with no evidence of disease; however, was eventually lost to follow-up. The two patients with MS succumbed to the cancer as a result of progressive disease and leukemia. Therefore, pathological examination may be important for the timely diagnosis and appropriate therapeutic regimen for primary hematological malignancy of the uterine cervix.

The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report

“…We were able to identify 57 cases of leukemic cervical tumors in published articles from 2002 to 2019 (Table 1 ). Patients often complain of vaginal bleeding at the onset of disease [ 6 , 7 ], it was the first symptom in the above case. FDG-PET/CT appears to be the best imaging option to assess the presence of extramedullary AML and effectively used to both search for other possible lesions and monitoring the response to therapy [ 19 – 21 ].…”

“…Garcia et al, USA, Spain, 2006 11 Cervix—27.3% (n = 3) Ovary—18.2% (n = 2) Uterine corpus—9% (n = 1) External genital organs—9% (n = 1) ≥ 2 gynecologic sites—36.5% (n = 4) 36.5% (n = 4) CT 64 (7) 40 RT 9 (1) 5 CT + alloBMT 9 (1) > 6 SI 73 (8) - 9 Cervix—11% (n = 1) Ovary—89% (n = 8) 22% (n = 2) CT 33 (3) 15 CT + alloBMT 11 (1) 10 7 [ 44 ] S.C.H. Kim et al, France, 2010 1 Cervix No CT + RT > 72 8 [ 45 ] H. Gill et al, China, 2012 1 Cervix, left pelvic cavity No CT 16 9 [ 7 ] W. Gui et al, China, 2019 2 Cervix, external genital organs (vagina), intrapelvic lymph nodes No SI + CT 21 Cervix, uterus, intrapelvic lymph nodes Yes CT 26 10 [ 46 ] A.S. Weingertner et al, France, 2009 1 Cervix, intrapelvic lymph nodes …”

“…MS of the gynecologic tract, in particular the cervix, is rare (up to 5.8–22.7% of all localizations). Vaginal bleeding is a very common presenting symptom of MS of the cervix or uterus [ 6 , 7 ]. Diagnosis of MS is difficult, especially in the absence of bone marrow involvement, and is based on a combination of clinical features, radiological investigations, and tissue biopsy [ 1 , 8 , 9 ].…”

Chloroma of the Bladder: A Case Report of Leukemia Progression Presenting as Hematuria

“…The genitourinary tract is rarely involved by MS. The kidney, bladder, prostate, testes, epididymis, and uterine cervix are among the documented sites of genitourinary involvement [ 11 , 12 , 13 , 14 , 15 ]. Patients with lower urinary tract MS can present with signs and symptoms related to urinary tract obstruction or urinary retention [ 16 ].…”

De novo myeloid sarcoma mimicking gynecological tumors: a retrospective case series of eight patients

“…Although very rare, gynecological oncologists may encounter patients with MS that mimics gynecological tumor, such as a pelvic, cervical, vaginal, vulvar, and even placental mass [ 13 – 16 ]. However, no specific treatment guidelines are available for these patients.…”